News

This Phase II trial is a double-blind, placebo-controlled, parallel group study that is designed to assess the safety and efficacy of senicapoc, administered once a day for two

The facility will evaluate new processes to complement its current proprietary technologies – Meltrex, Xellex, NanoMorph and smartCrystals – that target the formulation of soluble complex pharmaceutical substances.

The Czech Republic office, located in Prague, is led by Libor Hubacek, country manager for Averion in the Czech Republic. Dr Hubacek will oversee monitoring and regulatory activities

The patent claims are broad and include compositions of peptides for cancer immunotherapy as well as methods for inducing immune responses against tumor antigens in cancer patients. The

Permacol, which joins the company’s line of products following the acquisition of Tissue Science Laboratories, is available in the US, Europe, Canada and Korea and will be registered

Under the license agreement, CSL will obtain non-exclusive rights to use Potelligent technology platform to research, develop, manufacture, and commercialize antibody-dependent cellular cytotoxicity (ADCC)-enhanced antibodies for an undisclosed

Circassia has also entered into agreements with pharmaceutical manufacturers Excella and Hospira to establish a commercial-scale supply chain for the product. Circassia is developing dopexamine in a new

Mr De Vaere’s most recent position was as senior vice president, finance and administration and CFO of IDM Pharma, a biopharmaceutical company focused on the development of innovative

The Phase I study is an open-label, single center, ascending dose trial that will determine the safety and tolerance of multiple administrations of the synthetic retinoid drug in